Weil’s Antitrust team advised Allergan plc, a leading global pharmaceutical company, in the recently completed divestiture of its global generic pharmaceuticals business to Teva Pharmaceutical Industries Ltd, a transaction valued at approximately $39 billion.

Weil’s Antitrust team was led by partner Steven Newborn and includes partners Ann Malester and Jeff White, and associates Daniel Antalics, Benjamin Bauer and Lisa Madalone.

Weil has advised Allergan in numerous other prominent Antitrust matters including:

• Allergan’s approximately $160 billion merger agreement with Pfizer Inc. (November 23, 2015)
• Allergan’s approximately $2.1 billion acquisition of KYTHERA Biopharmaceuticals Inc. (June 18, 2015)
• Actavis plc’s approximately $70.5 billion acquisition of Allergan (November 17, 2014)